Modotuximab (Anti-Human EGFR Recombinant Antibody) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab contains a portion of Futuximab that binds to two independent, non-overlapping epitopes on EGFR. Modotuximab promotes cross-linking of EGFR on the cell surface and promotes EGFR cellular internalization and degradation. Modotuximab has antitumor activity in vivo.
References:
[1]. KeirST, et al. Sym004-induced EGFRelimination is associated with profound anti-tumor activity in EGFRvIIIpatient-derived glioblastoma models. J Neurooncol. 2018 Jul;138(3):489-498.
[2]. Modotuximab. IMGT Database.